Biologics

Questions discussed in this category

Is there a role for biologics to help patients with ABPA who are steroid responsive and have removed their allergen insult, but continue to have an elevated serum IgE and incomplete resolution of symptoms return to their baseline functional status?

0 Answers available

Which medications have the lowest risk of tuberculosis reactivation in patients with uncertain tuberculosis history and active rheumatologic disease?

2 Answers available

Would you start a TNF-I for seronegative non-erosive RA in a patient with positive ANA and sun sensitivity without other SLE features?

1 Answer available

Are there any known contraindications for IL-23 use in patients with psoriatic arthritis and CKD or ESRD?

1 Answer available

Do you hold tocilizumab for patients who are diagnosed with Covid and are with mild to moderate symptoms or non-hospitalized?

1 Answer available

What is the biologic of choice in a patient with RA and myasthenia gravis?

1 Answer available

How does a history of splenectomy alter how you counsel patients on the infection risk of TNF inhibitors or other biologics?

1 Answer available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

What is the biologic of choice in a patient with RA and history of non-melanoma skin cancer?

2 Answers available

What is your approach to dental prophylaxis for patients on biologics?

1 Answer available

Papers discussed in this category

Arthritis care & research, 2012-05

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Arthritis Rheumatol, 2016 Jan

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

N Engl J Med,

Clinical practice. Care of the asplenic patient.

Mediterr J Rheumatol, 2020 Jun 11

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies.

Curr Med Chem,

Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.

Pathology, 2017 Mar 11

The role of interleukin-17A in the pathogenesis of kidney diseases.

Related Topics